PRDS
NASDAQPardes Biosciences Inc.
Pardes Biosciences Inc. (PRDS) is a Medicinal Chemicals and Botanical Products company listed on NASDAQ. There were no new wire items for PRDS in the last 30 days. The most recent was published Sep 11, 2023.
Latest news
25 items- SECSEC Form 15-12G filed by Pardes Biosciences Inc.15-12G - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
- SECSEC Form EFFECT filed by Pardes Biosciences Inc.EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
- SECSEC Form EFFECT filed by Pardes Biosciences Inc.EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
- INSIDERSEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)SC 13D/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
- INSIDERSEC Form 4: Wiggans Thomas G closing all direct ownership in the company4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4: Varney Michael David closing all direct ownership in the company4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4 filed by Smaldone Alsup Laurie4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4 filed by Pottage John C Jr4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4: Lopatin Uri A closing all direct ownership in the company4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4: Lobell J Jay closing all direct ownership in the company4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4: Lacy Elizabeth H. closing all direct ownership in the company4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4: Henson Heidi closing all direct ownership in the company4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4 filed by Hamill Laura4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4 filed by Autor Deborah M.4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- INSIDERSEC Form 4: Auerbach Mark closing all direct ownership in the company4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
- SECSEC Form 25-NSE filed by Pardes Biosciences Inc.25-NSE - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
- SECSEC Form S-8 POS filed by Pardes Biosciences Inc.S-8 POS - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
- SECSEC Form POS AM filed by Pardes Biosciences Inc.POS AM - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
- SECSEC Form POS AM filed by Pardes Biosciences Inc.POS AM - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
- SECPardes Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
- SECSEC Form SC 13E3/A filed by Pardes Biosciences Inc. (Amendment)SC 13E3/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
- SECSEC Form SC 14D9/A filed by Pardes Biosciences Inc. (Amendment)SC 14D9/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
- PRPardes Biosciences Announces Closing of Tender OfferCARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.
- SECSEC Form SC 13E3/A filed by Pardes Biosciences Inc. (Amendment)SC 13E3/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
PRDS FAQ
8 questionsWhat does Pardes Biosciences Inc. do?
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.What is the latest news on PRDS?
Quantisnow has not tracked any new filings, ratings or press releases for PRDS in the last 30 days. The most recent wire item was published on September 11, 2023.Where does PRDS stock trade?
Pardes Biosciences Inc. (PRDS) is listed on NASDAQ.What sector and industry is PRDS in?
Pardes Biosciences Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did Pardes Biosciences Inc. go public?
Pardes Biosciences Inc. (PRDS) completed its IPO in 2021.What are analysts saying about PRDS?
Across the last 3 analyst actions on Pardes Biosciences Inc., there were 0 upgrades and 1 downgrade. The most recent action was from JMP Securities: Mkt Perform on 2023-07-18. Recent price targets cluster around $25.00.What companies are similar to PRDS?
Notable peers in the same industry include SMFL (Smart for Life Inc.), SQZ (SQZ Biotechnologies Company), VLON (Vallon Pharmaceuticals Inc.), MNMD (Mind Medicine (MindMed) Inc.), GRPH (Graphite Bio Inc.). Compare PRDS side-by-side with any of them on Quantisnow.How can I track PRDS on Quantisnow?
Quantisnow aggregates Pardes Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRDS to receive live email and push alerts on every new disclosure.